Tongkat Ali (Eurycoma longifolia): The Testosterone and Cortisol Modulation Research Guide
Tongkat ali — the root extract of Eurycoma longifolia — has generated a growing body of randomized controlled trial data around testosterone support, cortisol modulation, and body composition in aging populations. Unlike many herbal extracts evaluated only in animal models, several standardized extracts have been studied in double-blind human trials, making it one of the better-evidenced botanicals in the hormonal optimization space.
What Is Tongkat Ali?
Eurycoma longifolia is a flowering plant native to Southeast Asia, particularly Malaysia, Indonesia, and Thailand. Its root has a long history of traditional use in the region. The bioactive constituents most studied for endocrine effects are quassinoids (eurycomanone being the most characterized), eurypeptides, glycosaponins, and polysaccharides.
Commercially, the most studied standardized extract is LJ100®, a 100:1 water-soluble extract standardized to eurycomanone content, manufactured under the Physta® trade name by the Malaysian government's Forest Research Institute (FRIM). Most published human trials use this extract; results from non-standardized products may not extrapolate.
Molecular Profile
| Property | Detail |
|---|---|
| Source plant | Eurycoma longifolia Jack (Simaroubaceae) |
| Primary bioactives | Eurycomanone (quassinoid), eurypeptides, glycosaponins |
| CAS (eurycomanone) | 84633-29-2 |
| Molecular weight (eurycomanone) | 408.40 g/mol |
| Main studied extract | LJ100® / Physta® (100:1 water-soluble) |
| Standardization marker | Eurycomanone (typically 0.8–1.0%) |
| Research status | Multiple human RCTs; not an approved pharmaceutical |
| Half-life | Not firmly established in humans |
| Regulatory status | Dietary supplement (US); Tradisional/natural product (Malaysia) |
Mechanism of Action
Tongkat ali does not appear to act as a direct androgen receptor agonist, nor does it contain testosterone or precursors. The proposed mechanisms include:
LH-mediated Leydig cell stimulation. Several rodent studies and mechanistic human analyses suggest the extract may upregulate luteinizing hormone (LH) signaling, promoting endogenous testosterone biosynthesis in Leydig cells. However, not all human trials have measured LH, leaving this mechanism partially inferred.
Sex hormone-binding globulin (SHBG) displacement. Some researchers have proposed that eurycomanone or related compounds compete for SHBG binding, increasing the fraction of free testosterone. The evidence for this mechanism in humans is limited to observational endpoints rather than direct binding assays.
Cortisol suppression via HPA-axis modulation. A plausible secondary mechanism involves reducing cortisol output, which competes with testosterone biosynthesis at shared precursor steps (pregnenolone pathway). A clinically stressed population trial (Shawn Talbott et al., 2013) explicitly demonstrated this angle.
Phosphodiesterase inhibition. In vitro data suggest some quassinoids inhibit phosphodiesterases, which could modulate cyclic AMP signaling. Whether this contributes to in vivo hormonal effects at dietary supplement doses is unconfirmed.
What the Research Actually Shows
Testosterone in Hypogonadal and Aging Men
The most cited human study (Tambi et al., 2012, Evidence-Based Complementary and Alternative Medicine) enrolled 76 men with late-onset hypogonadism and gave 200 mg LJ100® daily for one month. Serum testosterone increased from a mean of 10.9 ± 3.3 nmol/L to 16.4 ± 4.9 nmol/L — a roughly 50% increase — with 90.8% of subjects returning to normal testosterone range (≥12.1 nmol/L). The study was open-label and uncontrolled, which limits interpretation; the population selected was specifically testosterone-deficient, so effects in eugonadal men may differ substantially.
A more rigorous double-blind placebo-controlled trial (Henkel et al., 2014, Andrologia) gave 300 mg LJ100® or placebo to 109 men and women aged 57–72 for five weeks. Testosterone increased significantly in the tongkat ali group compared to placebo (specific values varied by subgroup). Notably, this trial also reported improvements in DHEA levels and reduced SHBG, supporting a multi-pathway hormonal effect.
A 2021 systematic review (Leisegang et al., Phytotherapy Research) analyzed 11 human studies and concluded there was "moderate-quality evidence" for testosterone augmentation, with the largest effects in populations with documented hypogonadism or age-related decline. Effects in younger, eugonadal men were more modest and inconsistent.
Cortisol and Psychological Stress
Talbott et al. (2013, Journal of the International Society of Sports Nutrition) conducted a double-blind placebo-controlled crossover trial in 63 moderately stressed adults. After four weeks of 200 mg LJ100® daily, salivary cortisol was 16% lower in the tongkat ali group vs. placebo, while testosterone was 37% higher, and a composite "hormonal profile score" (testosterone:cortisol ratio) improved significantly. Self-reported tension, anger, and confusion also declined. This study has been influential because it explicitly targeted a non-hypogonadal population selected for stress rather than low testosterone.
Body Composition
A 2003 pilot trial by Hamzah and Yusof (British Journal of Sports Medicine) gave 100 mg tongkat ali extract or placebo to recreational athletes over five weeks combined with a training program. The tongkat ali group showed greater lean body mass gain and arm circumference increase than placebo. The sample was small (n=14 per group) and the extract was not LJ100®, making extrapolation cautious.
A more recent 12-week RCT in older adults (Leitão et al., 2021, Biology) using Physta® 400 mg/day found significant improvements in muscle strength (grip and leg press) and lean mass vs. placebo. This study is notable for its duration and use of a standardized extract.
Male Fertility Parameters
Multiple studies have examined semen parameters. Hamil et al. (2014, Asian Pacific Journal of Reproductive Medicine) conducted an open-label trial in 109 men with idiopathic infertility, giving 200 mg LJ100® for three months. Sperm motility, volume, and morphology improved in the majority of subjects, and pregnancy occurred in 14.7% of partners during the study period. Absence of a control group limits interpretation.
A controlled pilot study (Tambi and Imran, 2010, Asian Journal of Andrology) reported similar improvements in semen quality, with sperm concentration increasing from 18.3 to 21.0 × 10⁶/mL and motility from 20.5% to 44.4% after 9 months of 200 mg/day. Sample sizes were small.
Comparison to Similar Compounds
| Compound | Primary mechanism | Human RCT evidence | Typical dose | Key limitation |
|---|---|---|---|---|
| Tongkat Ali (LJ100®) | LH stimulation (?), SHBG displacement, cortisol reduction | Moderate (multiple small RCTs) | 200–400 mg/day | Most effects in deficient/aging populations |
| Ashwagandha (KSM-66) | Cortisol reduction, LH modulation | Moderate (multiple small RCTs) | 300–600 mg/day | Similar effect size; more cortisol data |
| Fadogia agrestis | Proposed LH stimulation | Minimal (rodent only) | Not established | No human trial data; potential hepatotoxicity signals |
| DHEA | Direct androgen precursor | Good (multiple RCTs) | 25–100 mg/day | Age-dependent response; supraphysiologic dosing concerns |
| Boron | SHBG displacement | Limited | 6–10 mg/day | Weak effect size in most trials |
Research Limitations
Several consistent methodological weaknesses appear across the tongkat ali literature:
Small sample sizes. Most trials enroll under 100 participants per group. The largest RCTs (Henkel 2014, Leitão 2021) approached statistical power thresholds but still leave effect sizes uncertain.
Population specificity. The clearest testosterone effects emerge in hypogonadal or stressed populations. Whether eugonadal men with normal testosterone see meaningful changes is less clear; some trials show minimal response in this subgroup.
Extract heterogeneity. A significant portion of published research uses LJ100® or Physta®. Studies using other extracts, powders, or non-standardized products cannot be reliably compared. The clinical literature does not generalize to arbitrary "tongkat ali" products.
Funding and publication bias. Several high-profile trials were funded by or conducted in partnership with the Malaysian government or extract manufacturers, which represents a conflict of interest even when blinding appears adequate.
Short durations. Most trials run 4–12 weeks, providing limited safety data for long-term use and leaving open whether effects are sustained.
No head-to-head testosterone comparison. No published trial has compared tongkat ali directly to TRT or other hormonal interventions in the same population.
Key Takeaways
- Tongkat ali, specifically standardized LJ100®/Physta® extract, has the most human RCT data of any "testosterone-supporting" botanical, with several placebo-controlled trials showing statistically significant effects.
- The strongest and most consistent effects are observed in men with documented hypogonadism, age-related testosterone decline, or significant psychological stress — not necessarily in eugonadal adults.
- Cortisol reduction is a well-supported secondary effect and may explain part of the apparent testosterone benefit through improved testosterone:cortisol ratios.
- Male fertility parameters (motility, morphology, volume) show improvements in multiple studies, though most lack robust controls.
- Body composition benefits (lean mass, strength) have been demonstrated in older adults over 12 weeks in at least one well-designed RCT.
- Extract standardization matters significantly; research results from LJ100® or Physta® should not be assumed to apply to non-standardized products.
- Longer-term safety data beyond 12 weeks is limited; the compound appears well-tolerated at 200–400 mg/day in published trials, but monitoring for androgenic effects is reasonable.
- Comparisons to ashwagandha suggest similar cortisol-modulating effects, while fadogia agrestis lacks human trial data entirely.
This article is for informational and research reference purposes only. Tongkat ali root extract is a dietary supplement, not an approved pharmaceutical or hormonal therapy. It should not be used as a substitute for clinically supervised testosterone replacement therapy. Individuals with hormone-sensitive conditions should consult a healthcare provider before use. Research findings summarized here reflect the current published literature and do not constitute medical advice.
Want a personalized protocol?
Take the assessment and we'll match you to the right research stack based on your goals.
Start your assessment →